Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study

Autor: Miklos Pless, R. Stahel, Anastase Spiliopoulos, Markus Furrer, Arnaud Roth, C. Von Briel, James Habicht, M. Wernli, Eva Hansen, Ralph A. Schmid, Martin Tötsch, Christine Joss, Fritz Egli, Hanspeter Honegger, H-B Ris, Thomas Cerny, Daniel C. Betticher, W. Weder, S-F Hsu Schmitz, Roger Stupp
Rok vydání: 2006
Předmět:
Male
Cancer Research
Lung Neoplasms
Time Factors
medicine.medical_treatment
Phases of clinical research
Docetaxel
Gastroenterology
Mediastinoscopy
Recurrence
Carcinoma
Non-Small-Cell Lung
Clinical Studies
ddc:616
ddc:617
medicine.diagnostic_test
Respiratory disease
downstaging
Middle Aged
Prognosis
Combined Modality Therapy
Survival Rate
Treatment Outcome
chemotherapy activity
Carcinoma
Non-Small-Cell Lung/diagnosis/drug therapy/surgery
Oncology
Chemotherapy
Adjuvant
Taxoids
Female
stage IIIA NSCLC
Lung Neoplasms/diagnosis/drug therapy/surgery
medicine.drug
Adult
medicine.medical_specialty
Taxoids/therapeutic use
Risk Assessment
Disease-Free Survival
Internal medicine
medicine
Carcinoma
Humans
Lung cancer
Survival rate
Aged
Neoplasm Staging
Chemotherapy
business.industry
medicine.disease
Surgery
long-term survivor
Cisplatin
Cisplatin/therapeutic use
Neoplasm Recurrence
Local
business
Follow-Up Studies
Zdroj: British journal of cancer, vol. 94, no. 8, pp. 1099-106
British Journal of Cancer, Vol. 94, No 8 (2006) pp. 1099-106
British Journal of Cancer
ISSN: 1532-1827
0007-0920
DOI: 10.1038/sj.bjc.6603075
Popis: The aim was to investigate the efficacy of neoadjuvant docetaxel–cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) non-small-cell lung cancer (NSCLC) patients. In all, 75 patients (from 90 enrolled) underwent tumour resection after three 3-week cycles of docetaxel 85 mg m−2 (day 1) plus cisplatin 40 or 50 mg m−2 (days 1 and 2). Therapy was well tolerated (overall grade 3 toxicity occurred in 48% patients; no grade 4 nonhaematological toxicity was reported), with no observed late toxicities. Median overall survival (OS) and event-free survival (EFS) times were 35 and 15 months, respectively, in the 75 patients who underwent surgery; corresponding figures for all 90 patients enrolled were 28 and 12 months. At 3 years after initiating trial therapy, 27 out of 75 patients (36%) were alive and tumour free. At 5-year follow-up, 60 and 65% of patients had local relapse and distant metastases, respectively. The most common sites of distant metastases were the lung (24%) and brain (17%). Factors associated with OS, EFS and risk of local relapse and distant metastases were complete tumour resection and chemotherapy activity (clinical response, pathologic response, mediastinal downstaging). Neoadjuvant docetaxel–cisplatin was effective and tolerable in stage IIIA pN2 NSCLC, with chemotherapy contributing significantly to outcomes.
Databáze: OpenAIRE
Externí odkaz: